Showing 3521-3530 of 7016 results for "".
The Role of Neurofilament Light Chain in MS Management
https://reachmd.com/programs/neurofrontiers/neurofilament-light-chain-ms-management/54243/Updates on the ACCORD Trial From the 2010 National Lipid Association Meeting
https://reachmd.com/programs/lipid-luminations/updates-on-the-accord-trial-from-the-2010-national-lipid-association-meeting/5588/Host Dr. Alan Brown broadcasts from the 2010 National Lipid Association meeting in Chicago. His guest is Dr. John R. Crouse, professor of medicine and public health sciences at Wake Forest University in Winston-Salem, North Carolina. They focus on the results from the ACCORD lipid study. BrouPre-Operative Cardiac Risk Assessment and Risk Reduction
https://reachmd.com/programs/heart-matters/pre-operative-cardiac-risk-assessment-and-risk-reduction/4195/For patients undergoing major non-cardiac surgery, perioperative management often focuses on recognition and treatment of cardiac risk factors and disease. Dr. Don Poldermans, professor of medicine and head of perioperative cardiac care at Erasmus Medical Center in Rotterdam, the Netherlands, joinsLifestyle Factors to Aid in Lowering Cholesterol
https://reachmd.com/programs/lipid-luminations/lifestyle-factors-to-aid-in-lowering-cholesterol/3506/Host Dr. Larry Kaskel welcomes Dr. Penny Kris-Etherton, PhD, RD to Lipid Luminations. Dr. Kris-Etherton is a distinguished professor of nutrition at Penn State University. The discussion will cover what health care professionals can do to increase cholestrol awareness in the general population as wdeCode MI: Another Tool to Assess Patient's MI Risk
https://reachmd.com/programs/clinicians-roundtable/decode-mi-another-tool-to-assess-patients-mi-risk/3291/Are we already able to assess our patients accurately for MI risk factors or is there another test that could provide more accuracy? Our guest today, Dr. Jeffrey Gulcher, chief scientific officer and co-founder of deCode Genetics tells host, Dr. Larry Kaskel about deCode MI. Learn how toCosibelimab Delivers Durable Responses in Advanced CSCC
https://reachmd.com/programs/project-oncology/cosibelimab-delivers-durable-responses-in-advanced-cscc/54699/The Next Chapter: SABCS 2025 and the Future of HR+ HER2− Breast Cancer Care
https://reachmd.com/programs/project-oncology/sabcs-2025-future-of-hr-her2-breast-cancer-care/36166/The 2025 San Antonio Breast Cancer Symposium (SABCS) brought forward key advances shaping the future of hormone receptor-positive, HER2-negative (HR+ HER−) advanced breast cancer care. From novel trial designs to emerging resistance pathways and supportive care considerations, new data are helping r6 Emerging Companies Poised to Redefine Medical Aesthetics
https://reachmd.com/topics/energy-based-devices/6-emerging-companies-poised-to-redefine-medical-aesthetics/49011/Elevating CKD-aP Care: New Frontier
https://reachmd.com/programs/cme/elevating-ckd-ap-care-new-frontier/36298/Review best practices in CKD-aP diagnosis, treatment and management, including the role of multidisciplinary care and shared decision-making to improve quality of life.From Pathway to Patient: Clinical Advances in PI3K-Directed Therapy for HR+/HER2- mBC
https://reachmd.com/programs/cme/From-Pathway-to-Patient-Clinical-Advances-in-PI3K-Directed-Therapy-for-HR-HER2-mBC/35975/Join Drs. Jhaveri and Kalinsky and get up to speed on the latest data on PI3K-directed therapies and their role in the treatment paradigm for HR+, HER2- mBC.